Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that
members of management will be panelists on two panel discussions at the
16th Annual BIO CEO & Investor Conference on Monday, February
10, 2014. President and CEO, Christopher Anzalone, Ph.D., and COO and
head of R&D, Bruce Given, M.D., will participate in discussions at 9:00
am EST titled, "Solution Development: Aiming the Whole Pipeline at a
Single Goal," and at 10:30am EST titled, "Delivering the [RNAi] Goods,"
Now in its sixteenth year, the BIO CEO & Investor Conference is the
largest investor conference focused on established and emerging publicly
traded and select private biotech companies. The conference is beng
held February 10-11 at the Waldorf Astoria in New York City.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
drug delivery technologies to develop targeted drugs based on the RNA
interference mechanism that efficiently silence disease-causing genes.
Arrowhead technologies also enable partners to create peptide-drug
conjugates that specifically home to cell types of interest while
sparing off-target tissues. Arrowhead's pipeline includes clinical
programs in chronic hepatitis B virus and partner-based programs in
obesity and oncology.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company's email list to receive news directly, please
send an email to firstname.lastname@example.org.
[ Back To NFVZone's Homepage ]